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Pharmacogenetics requires robust and affordable tests to determine genetic variability. This study 
compares three genotyping methods: gene re-sequencing, real time polymerase chain reaction (PCR) 
allelic discrimination and PCR-RFLP for the detection of a genetic variation (516G>T) in the gene which 
codes for the enzyme, CYP2B6, the main enzyme in the metabolic pathway of the antiretroviral drug, 
efavirenz. The CYP2B6 (516G>T) variant has reduced metabolic capacity. Twenty (20) samples obtained 
from human immunodeficiency virus acquired immunodeficiency syndrome (HIV/AIDS) positive 
patients on an efavirenz containing regimen were used to establish whether these methods produce the 
same CYP2B6 genotype results on the same samples. Results were directly compared for concordance 
and revealed a 100% correlation with all three methods. Comparison for cost of equipment and reagents 
required for each method revealed an order of: sequencing > real time-PCR > PCR-RFLP. This study 
demonstrates the reproducibility of these three methods and provides an opportunity for the clinical 
applicability in routine clinical practice.  
 





Pharmacogenetics, the effect of genetic variability on 
drug response with respect to efficacy and safety of 
drugs, is increasingly transforming the practice of med-
icine from one treatment/dose fits all to personalised 
treatment (Goldstein et al., 2003; O'Kane et al., 2003; 
Ingelman-Sundberg, 2008). Variation in genes coding for 
drug target proteins (receptors, transporters and enzymes) 
have been shown to affect the pharmacodynamics and 
pharmacokinetics of some drugs resulting in the respon-
der and non-responder patient phenotypes which in turn 
affects drug efficacy and safety (Sheffield and Phillimore, 
2009; Tozzi, 2010). In recognition of these developments, 
Food and Drug Administration (FDA), World Health Orga-
nisation (WHO), European Medicines Agency (EMA), the 
Pharmaceutical industry and other regulatory authorities 
have come up with guidelines on the conduct of pharma-
cogenetic studies, the validation of pharmacogenetic 
tests, and the clinical practice of personalised medicine 
(Kirchheiner et al., 2005). Over 70 drugs in the market 
now carry pharmacogenetics information and/or recom-
mendations to take into consideration their use and over 
20  Pharmacogenetic tests have been approved or are at 
various levels of approval 
(http://www.fda.gov/drugs/scienceresearch/researcharea
 






Pharmacogenetic findings that have been developed 
for clinical solutions have mainly been on genes that 
affect the pharmacokinetics of drugs (Sheffield and 
Phillimore, 2009). The importance of pharmacogenetics 
in the treatment of HIV/AIDS was first highlighted by the 
discovery of HLA-B*5701 single nucleotide polymorphism 
(SNP) as a high predictive biomarker for potentially fatal 
skin hypersensivity reaction to abacavir (Hetherington et 
al., 2002; Martin et al., 2004). A genetic test for this SNP 
was subsequently developed and approved by FDA in 
2008 
(http://www.fda.gov/drugs/scienceresearch/researcharea
s/pharmacogenetics/ucm083378.htm). The metabolism 
and disposition of efavirenz has been demonstrated to be 
mainly by CYP2B6 (Ward et al, 2003; Tsuchiya et al., 
2004; Rotger, 2007). Several SNPs of this enzyme have 
been shown to determine exposure levels of efavirenz 
with CYP2B6 G516T and CYP2B6 T983C being the most 
significant (Rotger et al., 2005). The frequency of CYP2B6 
G516T has been shown to be very high in people of 
African origin as compared to Caucasian and Oriental 
populations (Matimba et al., 2008). Pharmacokinetic 
simulation studies have led to the derivation of a 
pharmacogenetic based dosing algorithm that takes the 
CYP2B6G516T genotype into account. Patients homo-
zygous for this variant have been shown to need only a 
third (200 mg) of the standard dose (600 mg) to attain 
safe and efficacious levels (Nyakutira et al., 2008). 
Ongoing studies are evaluating this dosing algorithm in a 
greater number of patients. Given the potential clinical 
utility of this dosing algorithm, there is need for a pharma-
cogenetics diagnostic test for CYP2B6 polymorphism.  
A number of methods for determining the CYP2B6G516T 
polymorphism have been published; the PCR-RFLP 
method (Rotger et al., 2005), the real-time PCR allelic 
discrimination method (Applied Biosystems, Foster City, 
CA) and the direct sequencing method (Mardis, 2008). In 
this study, we have compared the performance of these 
three methods on a set of 20 samples. The rationale for 
this being the need to demonstrate the reproducibility of 
these methods on the same samples, thus guide interes-
ted diagnostic laboratories on methods to adopt for clini-
cal diagnostics. 
The comparison was also done with a view to guide 
choice of method to invest in by interested parties whilst 
considering the key elements of a pharmacogenetic test 
for successful clinical application. The key elements 
assessed were experimental/technical robustness, 
accessibility (availability of laboratory facilities that can 
offer test in a timely manner) and affordability (a favou-
rable cost-benefit ratio in resource limited settings). 
 
 
MATERIALS AND METHODS 
 
A total of 20 samples from HIV/AIDS patients from Wilkins Hospital 
in Harare receiving efavirenz (600 mg once daily) in combination 
with two nucleoside analogue inhibitors, stavudine and lamivudine,  




were analyzed. Ethical approval for this study was obtained from 
the Medical Research Council of Zimbabwe. Whole blood was 
collected in EDTA tubes from each patient. Total genomic DNA was 
isolated using the QIAamp DNA mini kit (QIAGEN, Hilden, 





Genotyping was done using a PCR-RFLP method according to 
Rotger et al. (2005). The forward (5’-GTCTGCCCATCTATAAAC-3’) 
and reverse (5’-CTGATTCTTCACATGTCTGCG-3’) primers were 
used to generate a 526 bp product. A no DNA control was included 
in all the reactions to check for contamination. Briefly, PCR was 
performed using the GeneAmp PCR system 9700 in a total reaction 
volume of 15 μL with 5 to 10 ng of genomic DNA and Taq DNA 
polymerase (Inqaba Biotech, South Africa). PCR conditions con-
sisted of an initial denaturation at 94°C for 3 min, followed by 35 
cycles of denaturation at 94°C for 20 s, annealing at 60°C for 20 s, 
and extension at 72°C for 1 min, and a final extension at 72°C for 
60 s. The PCR product was digested with BsrI (New England Bio-




TaqMan real-time PCR allelic discrimination 
 
Genotyping was carried out by TaqMan allelic discrimination with 
fluorogenic 5´ nuclease assays on an ABI 7500 Sequence Detec-
tion System (Applied Biosystems, Foster City, CA). SNPs were 
analyzed using the following validated TaqMan Genotyping Assay 
purchased from Applied Biosystems: rs3745274, Assay ID 
C___7817765_60 according to the manufacturer’s instructions. 
Amplification conditions consisted of an initial hold cycle at 94°C for 
10 min, followed by 50 cycles of denaturation at 92°C for 15 s, 
annealing and extension at 90°C for 1 min. A no DNA control was 





Briefly, PCR was performed using the GeneAmp PCR system 9700 
(Applied Biosystems, Foster City, CA) in a total reaction volume of 
20 μl with 10 ng of genomic DNA and Ex Taq DNA polymerase 
(Takara Bio, Shiga, Japan). PCR conditions consisted of an initial 
denaturation at 94°C for 5 min, followed by 40 cycles of denature-
tion at 94°C for 30 s, annealing at 60°C for 30 s, and extension at 
72°C for 1 min, and a final extension at 72°C for 5 min (Maimbo et 
al., 2012). Sequencing of the purified DNA sample was carried out 
using the 3730 x l DNA Analyzer (Applied Biosystems). Sequences 
were analyzed using the Sequencer software 4.8.  
 
 
RESULTS AND DISCUSSION 
 
Comparison of results obtained using the three methods 
revealed a 100% correlation. The following genotypes 
were observed, four homozygous wild type (516 GG), 
thirteen heterozygous (516 GT) and three homozygous 
variant (516 TT). Figures 1a and b show the results 
obtained with the TaqMan assay and PCR-RFLP, respec-
tively. Analysis of equipment and reagent cost for each 
method were also compared and were in the order: DNA 
sequencing > TaqMan allelic discrimination > PCR-RFLP. 
This comparison was done to assess if the different 
methods available for CYP2B6 G516T genotyping give 
the same results. Whereas the three methods have been 
used individually in different studies: the PCR-RFLP method 






Figure 1a. Amplification plot and allelic discrimination plot for samples genotyped for CYP2B6 G516T using the TaqMan allelic 
discrimination assay. Each assay contains two allele-specific probes and a primer pair to detect the specific SNP target. Increase in 
fluorescence signal occurs when probes that have hybridized to the complementary sequence are cleaved. The fluorescence signal 
generated by PCR amplification indicates which alleles are present in the sample. Sequence detection software determines which alleles 






Figure 1b. PCR-RFLP based detection of CYP2B6 G516T on an ethidium bromide stained with 2% agarose gel. The restriction 
digestion product size is shown by the two arrows pointing to 503, 267 and 236 bp. GG = homozygous wild type (RE digestion 
successful no 516 G>T SNP present, 267 and 236 bp bands seen on the agarose gel); TT = homozygous mutant (516 G>T SNP 




(Rotger et al., 2005), the real-time PCR (RT-PCR) allelic 
discrimination method (Applied Biosystems, Foster City, 
CA) and the direct sequencing method (Mardis, 2008), 
this was the first study to compare the results of these




Table 1. Comparison of advantages and disadvantages of the three methods used to genotype for the CYP2B6 G516T variant and estimated  
input costs for each method (breakdown costs for reagents and consumables available in the supplementary material).  
 
  RFLP-PCR  TaqMan Real-Time PCR Allelic 
Discrimination 
 Direct re-sequencing  
(1.)  Capital equipment cost: $5 000 - $15 
000 
(2.)  Estimated reagents and consumables 
cost: $50 per sample 
(3.) Poor Precision 
(4.) Low sensitivity 
(5.) Low resolution 
(6.) Non-Automated 
(7.) Size-based discrimination only 
(8.)  Ethidium bromide for staining is not 
very quantitative 
(9.) Post-PCR processing 
(1.) Capital Equipment Cost: $50,000-
$80,000 
(2. ) Estimated reagents and consumables 
cost: $100 per sample 
(3.)  Increased range of detection 
(4.) No post-PCR processing 
(5.) Collects data in the exponential growth 
phase of PCR 
(6.)  Increase in reporter fluorescent signal is 
directly proportional to the number of 
amplicons generated 
(7.) Simple and  Robust Chemistry 
(8.) Automated Real-Time Genotype Calling 
(1) Capital Equipment Cost: 
$150,000-$200,000 
(2) Estimated reagents and 
consumables cost: $110 per sample 
(3.)  Simple and Robust Chemistry 
(4.)  Simple Procedure, reagent 
components for the sequencing 
reaction in a ready reaction, pre-
mixed format 
(5.)  Quantitative allele signal 






methods in the same samples. This was a necessary 
study to give methodological confidence to the clinical 
diagnostic community wishing to invest in any of these 
methods. 
A general survey of diagnostic laboratories in Zimba-
bwe has shown that more than 50% have at least a PCR 
laboratory and a few own a real time PCR machine. This 
is part of an increasing trend of moving most traditional 
serological and enzyme linked immunosorbent assay 
(ELISA) based methods to DNA technology platforms. 
Given the potential impact of pharmacogenetics on 
healthcare, focus is now on the development of high-
throughput methods for SNP genotyping. All current 
genotyping methods combine methods for allele discrimi-
nation and signal detection (Twyman, 2005). The result 
obtained in this study will assist most laboratories in 
choosing the most cost-effective platform to use, since 
results are reproducible with all three methods tested.  
Edenburg and Liu (2009) state that an important issue 
in genotyping is to choose the appropriate technology for 
one’s goals and for the stage of experiment, taking into 
account sample numbers and resources. With over 20% 
of patients in Zimbabwe requiring CYP2B6 (516G>T) 
genetic test guided dose adjustment (Nyakutira et al., 
2008), the tremendous cost saving that can be realized 
from prescribing the right drug at the right dose for an 
efficacious and safe outcome in the use of efavirenz will 
have a favorable cost-benefit ratio.  
In terms of capital investment and cost of reagents, the 
PCR-RFLP platform is the most affordable. However, this 
method has several drawbacks as listed in Table 1. 
Although, both the TaqMan allelic discrimination assay 
and direct re-sequencing are expensive to set-up, the 
simple chemistries and automated nature of these two 
methods make them more ideal for daily routine work, 
especially for a laboratory that will be doing high 
throughput work. Also, there is no post-PCR processing 
which will allow the analyst more time to work on other 
assays.  
Adequate training is however required for the analyst to 
operate the sequencer and real-time PCR machine. Given 
the current results and despite the low investment and 
budgets for healthcare delivery systems in Africa, the 
availability of these three genotyping methods for CYP2B6 
516 G>T, allow different laboratories to choose a cost 
effective method that best suits them. In addition, differ-
ent laboratories can come together under a consortium 
and establish a centre where the genotyping tests can be 
done.  
In conclusion, with the explosion of genomics, persona-
lized medicine in part will mean checking genotypes to 
ensure patients get the right drug at the right dose from 
start of treatment (Altman et al., 2011). Therefore, it is 
worthwhile for laboratories in Zimbabwe and other African 
countries to consider investing into a genotyping method 
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